CHOICE-01 Study: New Insights on Lung Cancer Treatment
Author Information
Author(s): Dee Edward Christopher, Iyengar Puneeth
Primary Institution: Memorial Sloan Kettering Cancer Center
Hypothesis
Can novel biomarkers guide systemic treatment selection in lung cancer?
Conclusion
The CHOICE-01 study shows that toripalimab improves overall survival in patients with non-small-cell lung cancer without targetable mutations.
Supporting Evidence
- Toripalimab was associated with improved overall survival compared to placebo.
- The study demonstrated a significant benefit in non-squamous NSCLC patients.
- Patients with no detectable ctDNA in the toripalimab arm showed a higher response rate.
Takeaway
This study found that a new treatment called toripalimab helps people with a type of lung cancer live longer, especially if they don't have certain genetic mutations.
Methodology
Patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy with or without toripalimab.
Potential Biases
Potential bias due to the study being conducted in a specific geographic location.
Limitations
The control arm of the study may not reflect standard care for all patients, and the study was conducted in multiple institutions in China, which may limit generalizability.
Participant Demographics
Patients with locally advanced or metastatic non-small-cell lung cancer without targetable EGFR or ALK mutations.
Statistical Information
P-Value
0.69
Confidence Interval
95%CI 0.57–0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website